drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Autologous ROR1-targeted chimeric antigen receptor (CAR) T-cell therapy; engineered patient T cells expressing an anti-ROR1 CAR (with CD3ζ and co-stimulatory domains) administered after lymphodepletion to mediate immune cytotoxicity against ROR1-positive tumor cells.
nci_thesaurus_concept_id
C189050
nci_thesaurus_definition
A preparation of autologous T-lymphocytes that are genetically engineered to express a chimeric antigen receptor (CAR) that targets an as of yet unidentified tumor-associated antigen (TAA), with potential immunomodulatory and antineoplastic activities. Upon administration of autologous CAR T-cells RD14-01, the T-cells target, bind to and induce selective cytotoxicity in tumor cells expressing the TAA.
drug_mesh_term
Immunotherapy, Adoptive
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered to express an anti-ROR1 chimeric antigen receptor (with CD3ζ and co-stimulatory domains). After lymphodepletion and infusion, CAR engagement of ROR1 on tumor cells triggers T-cell activation, proliferation, cytokine release, and immune-mediated cytotoxic killing of ROR1-positive tumor cells independent of native TCR recognition.
drug_name
RD14-01
nct_id_drug_ref
NCT05748938